Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.
2.
3.
4.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
5.

Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.

Lindsay R, Watts NB, Lange JL, Delmas PD, Silverman SL.

Osteoporos Int. 2013 Aug;24(8):2345-52. doi: 10.1007/s00198-013-2332-7. Erratum in: Osteoporos Int. 2013 Aug;24(8):2375-6.

PMID:
23612793
6.

Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.

Chan SS, Rosenberg ZS, Chan K, Capeci C.

AJR Am J Roentgenol. 2010 Jun;194(6):1581-6. doi: 10.2214/AJR.09.3588.

PMID:
20489100
7.

[New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].

Yamaguchi T, Sugimoto T.

Clin Calcium. 2009 Jan;19(1):38-43. doi: CliCa09013843. Review. Japanese.

PMID:
19122263
8.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
9.

Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.

Berto P, Maggi S, Noale M, Lopatriello S.

Aging Clin Exp Res. 2010 Apr;22(2):179-88. doi: 10.3275/6816.

PMID:
20145427
10.

Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy.

Capeci CM, Tejwani NC.

J Bone Joint Surg Am. 2009 Nov;91(11):2556-61. doi: 10.2106/JBJS.H.01774.

PMID:
19884427
11.

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.

Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE; Fosamax Actonel Comparison Trial investigators..

Curr Med Res Opin. 2004 Dec;20(12):2031-41. Erratum in: Curr Med Res Opin. 2005 Feb;21(2):325.

PMID:
15706659
12.

Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.

Huang HT, Kang L, Huang PJ, Fu YC, Lin SY, Hsieh CH, Chen JC, Cheng YM, Chen CH.

Menopause. 2012 Dec;19(12):1360-3. doi: 10.1097/gme.0b013e318260143d.

PMID:
22968250
13.

Risedronate: a new oral bisphosphonate.

Umland EM, Boyce EG.

Clin Ther. 2001 Sep;23(9):1409-21. Review.

PMID:
11589256
14.

Unusual mid-shaft fractures during long-term bisphosphonate therapy.

Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS.

Clin Endocrinol (Oxf). 2010 Feb;72(2):161-8. doi: 10.1111/j.1365-2265.2009.03581.x.

PMID:
19302584
15.

The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.

Rietbrock S, Olson M, van Staa TP.

QJM. 2009 Jan;102(1):35-42. doi: 10.1093/qjmed/hcn130.

PMID:
18842684
16.

Aging bone and osteoporosis: strategies for preventing fractures in the elderly.

Ettinger MP.

Arch Intern Med. 2003 Oct 13;163(18):2237-46. Review.

PMID:
14557222
17.

Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.

Ringe JD, Farahmand P, Faber H, Dorst A.

Rheumatol Int. 2009 Jan;29(3):311-5. doi: 10.1007/s00296-008-0689-2.

PMID:
18762944
18.

Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).

Landfeldt E, Lang A, Robbins S, Ström O.

Calcif Tissue Int. 2011 Sep;89(3):234-45. doi: 10.1007/s00223-011-9511-3.

PMID:
21695544
19.

Differences in persistence among different weekly oral bisphosphonate medications.

Sheehy O, Kindundu CM, Barbeau M, LeLorier J.

Osteoporos Int. 2009 Aug;20(8):1369-76. doi: 10.1007/s00198-008-0795-8.

PMID:
19020921
20.

[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].

Kishimoto H.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:365-8. Review. Japanese. No abstract available.

PMID:
18161133

Supplemental Content

Support Center